|
|
|
Neurogen Begins Trial for Insomnia Drug
|
Business New Haven
4/29/2002
By: Lisa Micali
|
BRANFORD - Neurogen Corp. (NASDAQ: NRGN), a small-molecule drug-discovery and -development company, announced that Pfizer Inc. (NYSE: PFE) has commenced Phase I clinical trials of NGD 96-3, a drug candidate for treating insomnia, and one of several drug candidates being developed as the result of a collaboration with Pfizer. The Pfizer trial is a randomized, double-blind, placebo-controlled evaluation of the safety and pharmacokinetics of single rising oral doses of NGD 96-3, which selectively modulates receptors of the GABAA (gamma aminobutyric) neurotransmitter system.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
